Literature DB >> 11348034

Molecular mechanism of cardiac hypertrophy and development.

I Komuro1.   

Abstract

Congestive heart failure is a major issues for cardiologists and to fully understand heart failure, it is important to understand the mechanism of the development of cardiac hypertrophy. Hemodynamic overload, namely mechanical stress, is a major cause of cardiac hypertrophy and to dissect the signaling pathways from mechanical stress to cardiac hypertrophy, an in-vitro device by which mechanical stress can be imposed on cardiac myocytes of neonatal rats cultured in serum-free conditions has been developed. Passively stretching cardiac myocytes cultured on silicone membranes induced various hypertrophic responses, such as activation of the phosphorylation cascades of many protein kinases, expression of specific genes and an increase in protein synthesis. During this process, secretion and production of vasoactive peptides, such as angiotensin II and endothelin-1, were increased and they played critical roles in the induction of these hypertrophic responses. Candidates for the 'mechanoreceptor' that receives the mechanical stress and converts it into intracellular biochemical signals have been recently demonstrated. Gene therapy and cell transplantation are hopeful strategies for the treatment of heart failure and require an understanding of how normal cardiac myocytes are differentiated. A key gene that plays a critical role in cardiac development has been isolated. The cardiac homeobox-containing gene Csx is expressed in the heart and the heart progenitor cells from the very early developmental stage, and targeted disruption of the murine Csx results in embryonic lethality because of the abnormal looping morphogenesis of the primary heart tube. With a cardiac zinc finger protein GATA4, Csx induces cardiomyocyte differentiation of teratocarcinoma cells as well as upregulation of cardiac genes. Mutations of human CSX cause various congenital heart diseases including atrial septal defect, ventricular septal defect, tricuspid valve abnormalities and atrioventricular block.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11348034     DOI: 10.1253/jcj.65.353

Source DB:  PubMed          Journal:  Jpn Circ J        ISSN: 0047-1828


  11 in total

1.  Depletion of endogenous kallistatin exacerbates renal and cardiovascular oxidative stress, inflammation, and organ remodeling.

Authors:  Yuying Liu; Grant Bledsoe; Makato Hagiwara; Bo Shen; Lee Chao; Julie Chao
Journal:  Am J Physiol Renal Physiol       Date:  2012-07-18

2.  Balance between hypertrophic and hypoxic stimulus in caspase-3 activation during rat heart development.

Authors:  A Cataldi; C Rapino; G Bianchi; L Centurione; M Zingariello; C Di Giulio; A Antonucci
Journal:  J Mol Histol       Date:  2005-03       Impact factor: 2.611

3.  The dynamics of fibroblast-myocyte-capillary interactions in the heart.

Authors:  Stephanie L K Bowers; Thomas K Borg; Troy A Baudino
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

Review 4.  Cardiovascular Diseases and Zinc.

Authors:  Serhan Ozyildirim; Saltuk Bugra Baltaci
Journal:  Biol Trace Elem Res       Date:  2022-06-08       Impact factor: 3.738

5.  Mechanisms of endothelin-1-induced decrease in contractility in adult mouse ventricular myocytes.

Authors:  K Nishimaru; Y Miura; M Endoh
Journal:  Br J Pharmacol       Date:  2007-07-16       Impact factor: 8.739

Review 6.  Histone deacetylases in modulating cardiac disease and their clinical translational and therapeutic implications.

Authors:  Zhengke Wang; Yu Tina Zhao; Ting C Zhao
Journal:  Exp Biol Med (Maywood)       Date:  2020-07-29

7.  QiShenYiQi Pills, a compound in Chinese medicine, protects against pressure overload-induced cardiac hypertrophy through a multi-component and multi-target mode.

Authors:  Yuan-Yuan Chen; Quan Li; Chun-Shui Pan; Li Yan; Jing-Yu Fan; Ke He; Kai Sun; Yu-Ying Liu; Qing-Fang Chen; Yan Bai; Chuan-She Wang; Bing He; Ai-Ping Lv; Jing-Yan Han
Journal:  Sci Rep       Date:  2015-07-02       Impact factor: 4.379

8.  The POU4F2/Brn-3b transcription factor is required for the hypertrophic response to angiotensin II in the heart.

Authors:  Laura Mele; Lauren J Maskell; Daniel J Stuckey; James E Clark; Richard J Heads; Vishwanie S Budhram-Mahadeo
Journal:  Cell Death Dis       Date:  2019-08-14       Impact factor: 8.469

9.  Mutational screening of affected cardiac tissues and peripheral blood cells identified novel somatic mutations in GATA4 in patients with ventricular septal defect.

Authors:  Chunyan Cheng; Yuan Lin; Fan Yang; Wenjing Wang; Chong Wu; Jingli Qin; Xiuqin Shao; Lei Zhou
Journal:  J Biomed Res       Date:  2011-11

Review 10.  Emergence of Members of TRAF and DUB of Ubiquitin Proteasome System in the Regulation of Hypertrophic Cardiomyopathy.

Authors:  Ishita Gupta; Nishant K Varshney; Sameena Khan
Journal:  Front Genet       Date:  2018-08-21       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.